Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144799 | 0.83 | GPR119 (0.36) | ALOX5APFEN1GPR119LIPE | |
| SCHEMBL610838 | 0.83 | HCRTR1 (0.38) | HCRTR1GPR119 | |
| SCHEMBL609826 | 0.83 | HCRTR1 (0.38) | HCRTR1GPR119 | |
| SCHEMBL10145425 | 0.83 | GPR119 (0.36) | ALOX5APFEN1GPR119LIPE | |
| SCHEMBL297790 | 0.82 | HCRTR1 (0.39) | HCRTR1 | |
| SCHEMBL10144795 | 0.81 | SYK (0.41) | HCRTR1ALOX5APFEN1GPR119LIPE | |
| SCHEMBL7870010 | 0.79 | HCRTR1 (0.37) | HCRTR1ALOX5APFEN1GPR119 | |
| SCHEMBL10145372 | 0.76 | ALDH1A1 (0.41) | HCRTR1ALOX5APFEN1GPR119 | |
| SCHEMBL10145584 | 0.76 | GRM5 (0.36) | ALOX5APFEN1 | |
| SCHEMBL10144797 | 0.75 | HCRTR1 (0.57) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885ALOX5AP 624/4885FEN1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.